Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series
Authors:
- Carla MarcoCarla Marco
- Marta SimóMSMarta Simó
- Montse AlemanyMAMontse Alemany
- Carlos CasasnovasCCCarlos Casasnovas
- Raúl DomínguezRDRaúl Domínguez
- Noelia VilariñoNVNoelia Vilariño
- Mariona CalvoMCMariona Calvo
- Juan Martín-LiberalJMJuan Martín-Liberal
- Jesús BrenesJBJesús Brenes
- Joan Sabater-RieraJSJoan Sabater-Riera
- Jordi BrunaJBJordi Bruna
- Roser VelascoRVRoser Velasco
Open Access
- 24 December 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (1) , 130
Abstract
Immunotherapy with immune checkpoint inhibitors (ICIs) have been reported to induce de novo or exacerbate pre-existing Myasthenia Gravis (MG). We present a single center case series of patients who developed an immune-related myasthenia gravis (irMG) related with ICIs. We performed a retrospective chart review of the electronic medical records between 1 September 2017 and 2022. We report the clinical features, presentation forms, diagnostic workflows, general management and outcomes of six patients who received ICIs for different solid organ malignancies and developed an irMG frequently overlapping with immune-related myocarditis and/or myositis. The aim of the article is to describe the clinical features, treatment and outcomes of this challenging and potentially life-threating syndrome, comparing our data with those described in the literature. Differences between irMG and classic MG are highlighted.Keywords
Funding Information
- Instituto de Salud Carlos III (PI20/00283)
- CERCA Programme/Generalitat de Catalunya
This publication has 37 references indexed in Scilit:
- Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodiesNeurology, 2019
- Reversible spontaneous EMG activity during myasthenic crisis: Two case reportseNeurologicalSci, 2019
- Neurologic complications of immune checkpoint inhibitorsJournal of Neuro-Oncology, 2018
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- Nivolumab-related myasthenia gravis with myositis and myocarditis in JapanNeurology, 2017
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Abnormal spontaneous activity on needle electromyography in myasthenia gravisMuscle & Nerve, 2017
- Myasthenia GravisNew England Journal of Medicine, 2016
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Myasthenia gravisNeurology, 2000